| Type size: |
 |
 |
|
|
Press Releases
Sign up to receive email notifications of new Press Release.
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Monogram Appoints Oncologist to Board of Directors
Aug 21, 2008
|
10.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Aug 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that Christine A. White, M.D. has been appointed to the company's board of directors.
"Christine White brings to our board a wealth of experience in oncology, as a practicing oncologist as well as...
|
|
|
Medical Policy Guideline for Trofile(TM) Established By Wellpoint, Inc.
Aug 20, 2008
|
10.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Aug 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that Wellpoint, Inc. has established a national Medical Policy Guideline for Monogram's Trofile Assay.
Wellpoint's guidelines provide that HIV tropism testing with Trofile is considered medically ...
|
|
|
Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
Aug 07, 2008
|
7.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO and Chairman, is scheduled to present an update on the company's business at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3, 2008 at 11:30 a.m. (...
|
|
|
Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
Aug 04, 2008
|
11.9 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Aug 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced the launch of its PhenoSense(R) Integrase assay, built on Monogram's proprietary technology platform, PhenoSense(R). The assay directly measures the susceptibility of HIV to a new and potent class of ...
|
|
|
Monogram Announces 2008 Second Quarter Financial Results
Jul 29, 2008
|
24.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today reported financial results for the quarter ended June 30, 2008.
The Company had revenues of $16.1 million for the second quarter of 2008, 66% higher than $9.7 million in the second quarter of 2007. This gr...
|
|
|
Monogram Provides 2008 Second Quarter Reconcilation of Revenue and Gross Margin on a GAAP to Non-GAAP Basis
Jul 29, 2008
|
22.3 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 29, 2008 — Monogram Biosciences, Inc. (Nasdaq: MGRM) today provided 2008 second quarter reconciliation of total revenue and product gross margin on a GAAP to Non-GAAP basis....
|
|
|
Monogram Announces Issuance of Key Patents Related to VeraTag(TM) Technology
Jul 23, 2008
|
9.9 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that three key United States Patents for its proprietary VeraTag(TM) technology have been issued (United States Patent numbers 7,402,397; 7,402,398 and 7,402,399). The patents are broad and relate to...
|
|
|
Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
Jul 16, 2008
|
8.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Tuesday, July 29, 2008 at 4:30 p.m. (Eastern Time) to discuss second quarter 2008 financial results. The call will be hosted by Mr. William D. Young, Chairman and CE...
|
|
|
Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
Jul 08, 2008
|
14.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that, effective July 15, the HERmark(TM) Breast Cancer Assay will be available to physicians throughout the U.S. for assessment of HER2 status in patients with breast cancer. HERmark provides a precis...
|
|
|
Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
Jul 01, 2008
|
7.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO and Chairman, is scheduled to present an update on the company's business at the Collins Stewart LLC Fourth Annual Growth Conference on Tuesday, July 8, 2008 at 9:00 a.m. (E...
|
|
|
Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
Jun 18, 2008
|
11.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced today that the Company has signed an agreement with Gilead Sciences, Inc. to provide resistance testing and consultative services for Gilead's Elvitegravir Phase III studies. Monogram assays will be used ...
|
|
|
Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
Jun 16, 2008
|
12.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that data related to the enhanced performance of the company's HIV tropism assay were presented in an oral presentation at the 17th International HIV Drug Resistance Workshop in Sitges, Spain. Trofil...
|
|
|
Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
Jun 05, 2008
|
12.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced immediate availability of enhanced sensitivity in its Trofile assay. Trofile was introduced commercially upon FDA approval of Selzentry(TM) (maraviroc), Pfizer's first in class CCR5 antagonist, in Aug...
|
|
|
Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
Jun 02, 2008
|
13.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 2, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that scientific collaborators have presented additional clinical results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 total protein and homodimer levels and predict r...
|
|
|
Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
May 16, 2008
|
12.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., May 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that scientific collaborators will present results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 and predict response to Herceptin(R) (trastuzumab) in patients with me...
|
|
|
HER1 and HER3 VeraTag™ Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
May 01, 2008
|
11.1 KB
|
| |
SOUTH SAN FRANCISCO, May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that the company's HER1 and HER3 Quantitative Protein Assays are now available for clinical development use. Built on Monogram's VeraTag™ platform, the HER1 and HER3 assa...
|
|
|
Monogram Announces 2008 First Quarter Financial Results
May 01, 2008
|
22.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today reported financial results for the quarter ended March 31, 2008.
The Company had revenue of $14.8 million for the first quarter of 2008, 57% higher than $9.4 million in the first quarter of 2007. This growth...
|
|
|
Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
Apr 21, 2008
|
7.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Thursday, May 1, 2008 at 4:30 p.m. (Eastern Time) to discuss first quarter 2008 financial results. The call will be hosted by Mr. William D. Young, Chairman and CEO...
|
|
|
Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Apr 14, 2008
|
7.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO and Chairman, is scheduled to present a corporate overview at the Seventh Annual JMP Securities Research Conference on Wednesday, May 21, 2008 at 5:00 p.m. Eastern Time (2...
|
|
|
New York Medicaid Program Establishes Coverage for Trofile(TM)
Apr 08, 2008
|
11.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 8, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that New York Medicaid has established coverage and reimbursement for Monogram's Trofile Assay, a diagnostic used to determine patient candidacy for Pfizer's new HIV anti-viral medication Selze...
|
|
|
|
 |
| Click here to get Corporate Fact Sheet, Backgrounders, Annual Reports.
|
|
 |
|
 |
Click here to view recent HIV scientific publications.
Click here to view recent oncology scientific publications.
|
|
 |
|
|
